• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Sinaptica’s neurostim treatment for Alzheimer’s wins FDA breakthrough nod

Sinaptica’s neurostim treatment for Alzheimer’s wins FDA breakthrough nod

October 19, 2022 By Sean Whooley

Sinaptica Therapeutics LogoSinaptica Therapeutics announced today that it received FDA breakthrough device designation for its investigational SinaptiStim AD system.

Cambridge, Massachusetts-based Sinaptica designed its system to treat cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD).

The system creates a novel integration of neurostimulation and brain wave monitoring technologies. It combines those with a proprietary AI-derived personalization engine. Sinaptica said in a news release that SinaptiStim represents a new approach to treating patients suffering from dementia.

Under the FDA breakthrough program, Sinaptia receives priority regulatory review. The company can also maintain interactive communication with the FDA throughout the premarket review phase.

“Groundbreaking potential”

“We are excited that the FDA has recognized the groundbreaking potential of our SinaptiStim AD system with Breakthrough Device Designation,” said Rich Macary, president of Sinaptica Therapeutics. “This marks an important milestone for the company, as it helps establish our regulatory pathway for FDA clearance of our SinaptiStim AD system. We look forward to collaborating with the agency to address the significant unmet need in the treatment of Alzheimer’s disease by developing a novel, safe, effective, non-invasive, and personalized electromagnetic therapeutic for patients.

“We plan to continue working toward the initiation of our pivotal trial next year, as well as further advancing the emerging field of electromagnetic therapeutics given their unique ability to modulate key mechanisms of synaptic plasticity and network connectivity in targeted regions of the brain.”

Dr. Giacamo Koch and Emiliano Santarnecchi founded Sinaptica. Koch serves as a professor of physiology at the University of Ferrara, Italy. He also serves as director of the non-invasive brain stimulation laboratory at Santa Lucia Foundation in Rome.

Santarnecchi is an associate professor of radiology at Harvard Medical School. He also serves as director of the precision neuroscience and neuromodulation program at Massachusetts General Hospital. He directs the network control laboratory at the Boston hospital, too.

Filed Under: Business/Financial News, Food & Drug Administration (FDA), Implants, Neurological, Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: FDA, Sinaptica Therapeutics

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy